Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CARDIOVASCULAR ENDOCRINOLOGY

Vitamin D supplementation: a novel therapy for aldosteronism?

Nature Reviews Endocrinology volume 16, pages 303–304 (2020)Cite this article

Subjects

Available evidence demonstrates a crosstalk between the renin–angiotensin and the parathyroid hormone–vitamin D systems. A new study suggests that vitamin D supplementation can lower systolic blood pressure and plasma aldosterone levels in patients with primary aldosteronism.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Model of how vitamin D deficiency or insufficiency could lead to secondary hyperparathyroidism.

References

  1. Ismail, N. A., Kamaruddin, N. A., Azhar Shah, S. & Sukor, N. The effect of vitamin D treatment on clinical and biochemical outcomes of primary aldosteronism. Clin. Endocrinol. https://doi.org/10.1111/cen.14177 (2020).

    Article  Google Scholar 

  2. Rossi, G. P. Primary aldosteronism: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 74, 2799–2811 (2019).

    Article  CAS  Google Scholar 

  3. Gao, X. et al. The crosstalk between aldosterone and calcium metabolism in primary aldosteronism: A possible calcium metabolism-associated aberrant “neoplastic” steroidogenesis in adrenals. J. Steroid Biochem. Mol. Biol. 193, 105434 (2019).

    Article  CAS  Google Scholar 

  4. Mazzocchi, G., Aragona, F., Malendowicz, L. K. & Nussdorfer, G. G. PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells. Am. J. Physiol. Metab. 280, E209–E213 (2001).

    CAS  Google Scholar 

  5. Chhokar, V. S. et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111, 871–878 (2005).

    Article  CAS  Google Scholar 

  6. Maniero, C. et al. Primary hyperparathyroidism with concurrent primary aldosteronism. Hypertension 58, 341–346 (2011).

    Article  CAS  Google Scholar 

  7. Maniero, C. et al. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J. Hypertens. 30, 390–395 (2012).

    Article  CAS  Google Scholar 

  8. Rossi, G. P. et al. Hyperparathyroidism can be useful in the identification of primary aldosteronism due to aldosterone-producing adenoma. Hypertension 60, 431–436 (2012).

    Article  CAS  Google Scholar 

  9. Lenzini, L. et al. PTH modulation by aldosterone and angiotensin II is blunted in hyperaldosteronism and rescued by adrenalectomy. J. Clin. Endocrinol. Metab 104, 3726–3734 (2019).

    Article  Google Scholar 

  10. Holick, M. F. et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy

    Gian Paolo Rossi & Livia Lenzini

Authors
  1. Gian Paolo Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Livia Lenzini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gian Paolo Rossi.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rossi, G.P., Lenzini, L. Vitamin D supplementation: a novel therapy for aldosteronism?. Nat Rev Endocrinol 16, 303–304 (2020). https://doi.org/10.1038/s41574-020-0359-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-020-0359-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing